RVNC - Revance Therapeutics EPS beats by $0.06 beats on revenue August, 05 2021 05:12 PM Revance Therapeutics Inc. Revance Therapeutics (NASDAQ:RVNC): Q2 GAAP EPS of -$1.07 beats by $0.06. Revenue of $18.8M (+6166.7% Y/Y) beats by $3.32M. Press Release For further details see: Revance Therapeutics EPS beats by $0.06, beats on revenue